abstract |
Disclosed is a therapeutic agent that can be used to treat IgA1 deposition disease. The present invention discloses the use of bacterial IgA1 protease to treat IgA1 deposition in tissues and organs. Since bacterial IgA1 protease specifically cleaves IgA1 molecules, it provides a means to specifically cleave and remove IgA1 deposits. Accordingly, a therapeutic agent for the treatment of diseases characterized by IgA1 deposition is provided. In particular, therapeutic agents for treating IgA nephropathy, herpetic dermatitis (DH), and Henoch-Schönlein purpura (HS) are disclosed. [Selection figure] None |